Stereospecific Synthesis, Structure−Activity Relationship, and Oral Bioavailability of Tetrahydropyrimidin-2-one HIV Protease Inhibitors
- 10 December 1998
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (1) , 135-152
Abstract
The use of tetrahydropyrimidinones as an alternate scaffold for designing HIVPR inhibitors has advantages, over the previously disclosed hexahydro-1,3-diazepin-2-ones, of being more unsymmetrical (different P1/P1‘), less crystalline, more soluble, and more lipophilic (mono-ol vs diol). They show a better translation of Ki to IC90 for the more polar P2 groups that in general give the more potent enzyme inhibitors. Structure−activity relationship (SAR) studies of the tetrahydropyrimidinones showed that the phenylethyl P1‘ substituent, the hydroxyl group, and the urea carbonyl are all critical for good activity. However, there was significant flexibility in the possible P2/P2‘ substituents that could be used. Many analogues that contained identical or different P2/P2‘ substituents, or only one P2 substituent, were found to have excellent enzyme potency and several had excellent antiviral potency. Several of these compounds were examined for oral bioavailability in the rat or the dog at 10 mg/kg. However, the oral bioavailability of the tetrahydropyrimidinones was, in general, less than the corresponding hexahydro-1,3-diazepin-2-ones. Unfortunately, when all factors are considered, including potency, protein binding, solubility, bioavailability, and resistance profile, the tetrahydropyrimidinones did not offer any advantage over the previously disclosed hexahydro-1,3-diazepin-2-ones series.Keywords
This publication has 15 references indexed in Scilit:
- Stereospecific, Stereoselective Rearrangement of Hexahydro-1,3-diazepin-2-ones to Tetrahydropyrimidin-2-ones and Imidazolidin-2-ones, a Useful Route for the Synthesis of HIV Protease InhibitorsThe Journal of Organic Chemistry, 1998
- Nonsymmetric P2/P2‘ Cyclic Urea HIV Protease Inhibitors. Structure−Activity Relationship, Bioavailability, and Resistance Profile of Monoindazole-Substituted P2 AnaloguesJournal of Medicinal Chemistry, 1998
- Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2′ groupsBioorganic & Medicinal Chemistry Letters, 1998
- Design, Synthesis, and Evaluation of Tetrahydropyrimidinones as an Example of a General Approach to Nonpeptide HIV Protease InhibitorsJournal of Medicinal Chemistry, 1997
- Cyclic Urea Amides: HIV-1 Protease Inhibitors with Low Nanomolar Potency against both Wild Type and Protease Inhibitor Resistant Mutants of HIVJournal of Medicinal Chemistry, 1997
- Potent cyclic urea HIV protease inhibitors with benzofused heterocycles as P2/P2′ groupsBioorganic & Medicinal Chemistry Letters, 1996
- Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450Chemistry & Biology, 1996
- HIV Protease Inhibitory Bis-benzamide Cyclic Ureas: A Quantitative Structure−Activity Relationship AnalysisJournal of Medicinal Chemistry, 1996
- Effect of grapefruit juice on blood cyclosporin concentrationThe Lancet, 1995
- Reactions of 2-acyloxyisobutyryl halides with nucleosides. I. Reactions of model diols and of uridineJournal of the American Chemical Society, 1973